Alejandro Rojas | Immunology Cellular Interactions | Best Researcher Award

Published on by Cell Biologist

Assist. Prof. Dr. Alejandro Rojas | Immunology Cellular Interactions | Best Researcher Award

Assist. Prof. Dr. Alejandro Rojas | Austral University of Chile | Germany

Dr. Alejandro Alfredo Rojas Fernández is a distinguished Chilean molecular biotechnologist and neuroscientist, currently serving as CEO of Berking Theranostics UG in Hamburg, Germany, and Assistant Professor at the Universidad Austral de Chile. With over two decades of research spanning neurodegeneration, immunology, and viral pathogenesis, Dr. Rojas-Fernández has emerged as a leading expert in molecular diagnostics and theranostics. His innovative work has significantly impacted global health, notably through his contributions to SARS-CoV-2 research and senolytic therapies. A dual academic and entrepreneur, he bridges fundamental science and clinical application, actively publishing in top-tier journals such as Nature Aging, Molecular Psychiatry, and Journal of Cell Biology. Fluent in interdisciplinary collaboration, his efforts have been internationally recognized with multiple honors. With a passion for translational science, Dr. Rojas-Fernández continues to inspire the next generation of biomedical innovators through mentorship and leadership in biotechnology and neuroscience.

Publication Profile:

Orcid

Education:

Dr. Alejandro Rojas-Fernández earned his PhD in Biology from the University of Konstanz, Germany (2006–2010), where his research focused on the regulation of Hdm2/HdmX-mediated ubiquitination and neddylation—mechanisms central to protein stability and cancer biology. Prior to his doctorate, he completed his engineering degree in Molecular Biotechnology (2004–2005) and his B.Sc. in Molecular Biotechnology Engineering (2000–2004) at the Faculty of Sciences, University of Chile—one of Latin America’s leading research institutions. His multidisciplinary education integrates molecular biology, neurobiology, immunology, and translational medicine, equipping him with the foundational and advanced tools to tackle complex biomedical challenges. Dr. Rojas-Fernández’s academic training has been marked by academic excellence and international mobility, enabling him to collaborate and lead research projects across Europe and Latin America.

Experience:

Dr. Rojas-Fernández brings over 20 years of experience in translational biomedical research, academia, and biotech innovation. As CEO of Berking Theranostics UG, he spearheads the development of personalized diagnostic platforms and therapeutics, with a focus on neurodegenerative and inflammatory diseases. In his role as Assistant Professor at Universidad Austral de Chile (20% appointment), he leads the Medical Biotechnology Laboratory within the Centre for Interdisciplinary Studies on the Nervous System (CISNe), contributing to scientific training and cutting-edge research. He previously trained and collaborated at institutions such as the University of Dundee, University of Queensland, and University of Constance, advancing molecular mechanisms of SUMOylation, proteostasis, inflammasome biology, and viral-host interactions. His interdisciplinary expertise allows him to translate complex cellular insights into tangible clinical applications, and his leadership has resulted in high-impact publications, product pipelines, and strategic biotech partnerships in Europe and Latin America.

Awards and Honors:

Dr. Rojas-Fernández has received multiple prestigious honors recognizing his innovative biomedical research. In February 2025, he was named “Innovator of the Month” by Hamburg Invest for groundbreaking biotech contributions in Germany. He was awarded the Medal of the City of Valdivia for his vital role in controlling the SARS-CoV-2 pandemic, one of the highest local honors in Chile. Additionally, he received the 2nd of October Medal for Science and Innovation, recognizing his scientific leadership in Chile’s Los Ríos region. These accolades underscore his impact on global public health, neurodegenerative research, and biotechnology entrepreneurship. His consistent recognition reflects a career dedicated to translational excellence, fostering international collaboration, and advancing science for the benefit of society. His scientific achievements continue to inspire innovation and interdisciplinary approaches within the global scientific community.

Research Focus:

Dr. Alejandro Rojas-Fernández’s research centers on cellular stress responses, ubiquitin/SUMO signaling, neurodegeneration, and host-pathogen interactions. A core focus is the molecular crosstalk between autophagy, protein quality control, and inflammasome activation in brain and immune cells. He has made significant advances in understanding the effects of SARS-CoV-2 on microglia, mechanisms of senescence in aging brains, and nanobody-based viral neutralization. His studies also explore the intersection of endoplasmic reticulum stress and neurodegenerative pathways, using high-content screening and proteomics to uncover therapeutic targets. He actively translates molecular insights into diagnostics and theranostic tools, positioning him at the forefront of personalized medicine. As CEO of a biotech startup, he is developing platforms that integrate biomarker discovery with AI for neuroinflammation profiling. His research bridges fundamental biology and clinical applications, promoting innovative therapies for Alzheimer’s, Parkinson’s, cancer, and viral infections.

Publications Top Notes: 

  1. Negative Modulation of Macroautophagy by Stabilized HERPUD1… – Front Cell Dev Biol, 2022

  2. SARS-CoV-2 drives NLRP3 inflammasome activation in human microglia… – Mol Psychiatry, 2022

  3. The p97/VCP segregase is essential for arsenic-induced degradation of PML… – J Cell Biol, 2023

  4. Lack of Parkinsonian Pathology after Proteasome Inhibitor Injection… – Front Aging Neurosci, 2021

  5. NSPA modulates postsynaptic NMDAR stability… – BMC Biol, 2020

  6. Role of PSMD14 in Golgi-to-ER transport and APP processing – Cells, 2020

  7. WDR90 in NLRC4 inflammasome and Salmonella resistance – Dev Comp Immunol, 2019

  8. Proteomic identification of APC interaction partners – Mol Cancer Res, 2019

  9. DHX15 regulates CMTR1-dependent gene expression – Life Sci Alliance, 2018

  10.  Membrane ruffling by polarized stim1 and orai1 – Sci Reports, 2017

Conclusion:

Dr. Alejandro Alfredo Rojas Fernández stands out as a pioneering researcher who consistently delivers scientifically rigorous, socially impactful, and clinically relevant work. His career spans critical sectors—basic research, applied biotechnology, and public health—making him a model example of the translational scientist. With accolades from both European and Latin American institutions and a track record of high-impact publications, Dr. Rojas exemplifies what it means to be a globally relevant and community-driven scientist. His work during the COVID-19 pandemic, innovations in molecular neuroscience, and leadership in therapeutic biotechnology underscore his immense value to the global research community. In conclusion, he is not only a suitable but a highly deserving candidate for the Best Researcher Award.

Shima Shafiee | Cell Structure Analysis | Best Researcher Award

Published on by Cell Biologist

Dr. Shima Shafiee | Cell Structure Analysis | Best Researcher Award

Dr. Shima Shafiee, Razi University, Iran

Shima Shafiee is an accomplished Iranian researcher specializing in computer systems architecture and bioinformatics, with a strong focus on machine learning applications in biological data analysis. She recently earned her Ph.D. in Computer Engineering from Razi University, where she focused on predictive modeling of protein-peptide binding interactions. Currently under consideration at the IDEL Lab, Shahid Bahonar University of Kerman, Shima has authored numerous national and international publications. With a rich background in algorithm optimization and artificial intelligence, her research stands at the intersection of computational biology, deep learning, and evolutionary algorithms. Shafiee’s work has contributed to the development of predictive tools in bioinformatics, such as DP-site and SPPPred, and she consistently ranks at the top of her academic cohort. Her ability to integrate traditional computer engineering concepts with advanced biological research makes her a notable candidate for the Best Researcher Award.

Publication Profile: 

Google Scholar

Strengths for the Award:

  1. Strong Academic Foundation
    Dr. Shafiee has a stellar academic record, graduating first in her Ph.D. class at Razi University with a CGPA of 3.77 and a thesis grade of 3.98, under the supervision of respected experts in computer engineering and bioinformatics.

  2. Innovative Interdisciplinary Research
    Her research bridges computer systems architecture, machine learning, and bioinformatics, with notable contributions to protein-peptide binding prediction, a critical domain in drug discovery and computational biology.

  3. High-Impact Publications
    She has published in IEEE/ACM Transactions, Applied Soft Computing, and Methods, reflecting both quality and visibility in international forums. Tools like SPPPred and DP-site demonstrate her practical impact in bioinformatics.

  4. Research Originality and Versatility
    Dr. Shafiee has developed hybrid models combining genetic programming, support vector machines, and deep learning, with practical tools and open-source contributions.

  5. Early Recognition and Outreach
    She has been active in academic dissemination since 2015, with selected papers in national and international conferences, showing early promise and consistency.

  6. Teaching and Mentorship
    Through her roles as a lecturer at multiple institutions, she has contributed to academic growth at the grassroots level.

Areas for Improvement:

  1. International Collaboration & Visibility
    While her publication quality is strong, Dr. Shafiee could expand her global visibility through collaborations with international research labs, EU Horizon, or NIH-funded projects.

  2. Post-Ph.D. Grant Applications
    She could benefit from applying for independent research grants or postdoctoral fellowships to lead projects that could shape the future of AI in biology.

  3. Open-Source Software and Data Availability
    While her models are impactful, increased accessibility via open-source repositories (e.g., GitHub) would boost reproducibility and encourage broader adoption.

  4. Industry Impact Metrics
    More emphasis on industry collaborations, patents, or application of models in clinical/biotech settings would enhance translational impact.

Education:

Shima Shafiee completed her Ph.D. in Computer Engineering (2016–2024) from Razi University, specializing in Computer Systems Architecture. Her dissertation titled “Application of learning-based models in predicting of protein-peptide binding interactions” earned her a thesis grade of 3.98/4.00 and an overall CGPA of 3.77. She worked under the guidance of Dr. Abdolhossein Fathi and Dr. Ghazaleh Taherzadeh, focusing on bioinformatics using deep learning, ensemble learning, and evolutionary algorithms. Prior to her Ph.D., she was ranked third in her Master’s program (2015). Shafiee’s educational background is rooted in computational problem-solving, algorithm development, and cross-disciplinary research involving biological data. Her consistent academic excellence and high-ranking performance culminated in her being recognized as the top Ph.D. student in 2025, a testament to her dedication and scholarly capabilities. Her education blends rigorous theory with innovative applied research, making her exceptionally well-prepared for high-impact contributions in academia and industry.

Experience:

Shima Shafiee’s experience spans both academic and applied computer engineering roles. She began her journey with an internship at Kimia Pardaz Pars Company (2013). Between 2015 and 2016, she served as a lecturer for computer fundamentals at Fajr High School and Al-Zahra Seminary School in Jiroft, where she taught introductory computer science to pre-university students. These experiences highlight her foundational teaching skills and outreach to educational institutions in her community. Her major academic contribution began during her Ph.D., where she collaborated with IDEL Lab and contributed to developing tools like SPPPred and DP-site, combining genetic programming, support vector machines, and deep learning to predict protein-peptide binding regions. Her experience uniquely blends educational outreach, algorithmic development, and publication-driven research in machine learning, optimization, and computational biology, reflecting her versatility and impact across the scientific and academic spectrum.

Awards & Honors:

Shima Shafiee has earned multiple distinctions recognizing her academic and research excellence. In 2015, she was named the third-place student in her Master’s program, demonstrating early academic excellence. Her continuous dedication to research and scholarship led her to be recognized as the first-place student in her Ph.D. program in 2025. One of her papers was selected at the 2nd International Congress of Electrical Engineering, Computer Science, and Information Technology (2015), highlighting the innovation and relevance of her early research in optimization algorithms. Her high publication output, including appearances in top-tier venues like IEEE/ACM Transactions on Computational Biology and Bioinformatics and Applied Soft Computing, reflects a consistent standard of excellence. These honors collectively showcase her as a standout figure in her field, with both academic and applied contributions acknowledged at national and international levels.

Research Focus:

Shima Shafiee’s research lies at the intersection of machine learning, bioinformatics, and computational systems engineering. Her primary focus is the prediction of protein-peptide binding interactions using intelligent algorithms such as genetic programming, ensemble models, and deep learning techniques. She has proposed several innovative hybrid models combining sequence-based and structure-based features to identify critical interaction residues. Her doctoral thesis and publications have led to the development of tools like SPPPred and DP-site, which aid in biological sequence analysis, with applications in drug discovery, protein function prediction, and biomedical engineering. Shafiee also has a strong background in optimization algorithms, especially particle swarm optimization (PSO), applied to computationally intensive problems like bin packing. Her ability to blend theoretical computing with practical biological data analysis makes her contributions valuable to both computational scientists and biologists, and positions her as a leading candidate for research recognition awards in AI and bioinformatics.

Publications Top Notes: 

  • 🧠 SPPPred: sequence-based protein-peptide binding residue prediction using genetic programming and ensemble learning (IEEE/ACM TCBBS, 2022)

  • 🔍 Prediction of protein–peptide-binding amino acid residues regions using machine learning algorithms (CSICC, 2021)

  • 🧬 Combination of genetic programming and SVM-based prediction of protein-peptide binding sites (Journal of Computing and Security, 2021)

  • 🧪 Prediction of protein–peptide binding residues using classification algorithms (IEEE Bioengineering Conf, 2020)

  • 🧠 A Review of the Uses of AI in Protein Research (Peptide Science Conf, 2019)

  • 🤖 DP-site: dual deep learning method for protein-peptide interaction site prediction (Methods, 2024)

  • 🧬 Protein-peptide interaction region prediction using generative sampling & ensemble DL (Applied Soft Computing, 2025)

  • 🧠 Comparing classification vs. segmentation predictors in protein-peptide interaction (CSICC, 2025)

  • 🧬 Leveraging structure-based and learning-based predictors in protein-peptide interaction (ICCKE, 2024)

  • 📘 Application of learning-based models in protein-peptide binding (Ph.D. Dissertation, 2024)

Conclusion:

Dr. Shima Shafiee is a highly suitable candidate for the Best Researcher Award based on her academic excellence, interdisciplinary research achievements, and consistent contributions to the fields of artificial intelligence and bioinformatics. Her ability to bridge computer science and biological challenges has resulted in meaningful and applicable solutions. She has displayed originality, depth, and foresight in her work, developing novel methods that align with modern computational biology trends.

Sukanta Nath | Cancer Research | Distinguished Scientist Award

Published on by Cell Biologist

Dr. Sukanta Nath | Cancer Research | Distinguished Scientist Award

Dr. Sukanta Nath, Atal Bihari Vajpayee Regional Cancer Centre, India

Dr. Sukanta Nath is a dedicated Research Scientist with over 13 years of experience in molecular biology, virology, and cancer research. He currently serves at the Atal Bihari Vajpayee Regional Cancer Centre, Agartala, Tripura, where he has led several impactful studies in oral cancer patient care. Holding a Ph.D. in Biotechnology from Gauhati University, Dr. Nath has consistently demonstrated excellence in scientific inquiry, especially in clinical intervention studies. His collaborative works with clinical and academic experts have produced over 10 peer-reviewed publications in reputed journals. Dr. Nath’s research emphasizes evidence-based nursing practices, molecular diagnostics, and the improvement of post-surgical outcomes in cancer patients. Known for his commitment to translational research, Dr. Nath is playing a pivotal role in bridging molecular science with patient-centered care in North-East India. His multidimensional expertise and scholarly contributions make him a deserving candidate for recognition as a Distinguished Scientist.

Publication Profile: 

Scopus

Strengths for the Award:

  1. Extensive Research Experience:
    With over 13 years of hands-on experience in molecular biology, cancer research, and virology, Dr. Nath has a well-established research career that aligns with the award’s standards.

  2. Focused Contributions to Cancer Research:
    His work at Atal Bihari Vajpayee Regional Cancer Centre has significantly contributed to oral cancer patient management, particularly through randomized intervention studies improving postoperative recovery and mental health.

  3. High Research Output:
    He has authored or co-authored 10+ peer-reviewed publications, many of which focus on novel and under-explored aspects such as nursing intervention in cancer care—a progressive and human-centered approach.

  4. Multidisciplinary Approach:
    Dr. Nath bridges molecular diagnostics, clinical research, and public health, evident in his work on HPV molecular epidemiology and AML treatment reviews.

  5. Collaborative and Institutional Impact:
    His collaborations with clinicians, nurses, and academic institutions highlight his team-oriented and translational research vision, helping integrate academic outputs into real-world healthcare.

Areas for Improvement:

  1. International Exposure:
    Dr. Nath could enhance his academic profile with international fellowships, collaborative projects, or presentations at global conferences, which would add broader recognition and perspective to his impactful regional work.

  2. Grant Acquisition & Leadership Roles:
    Documented principal investigator roles or research funding/grant awards would strengthen his leadership credentials in scientific research.

  3. Recognition & Awards:
    While he has a commendable publication record, more national or state-level recognitions, fellowships, or memberships in professional bodies (like ICMR, DBT, etc.) would boost his candidacy for national-level honors.

Education:

Dr. Sukanta Nath’s academic foundation is rooted in the biological sciences, beginning with a B.Sc. in Botany, Zoology, and Physiology from Calcutta University (2003, First Class). He went on to complete his M.Sc. in Biotechnology from Utkal University in 2006, securing First Class (67%). His research potential culminated in a Ph.D. in Biotechnology from Gauhati University, awarded in 2018, where he specialized in molecular biology and translational biomedical science. His education reflects a progressive mastery of theoretical and applied biotechnology, allowing him to engage in complex interdisciplinary research. Despite modest early academic challenges in higher secondary and matriculation, Dr. Nath’s academic trajectory sharply ascended, reflecting perseverance and intellectual growth. His doctoral training equipped him with specialized skills in molecular diagnostics, research design, and bioanalytical tools, which now form the backbone of his professional research work in cancer and infectious disease.

Professional Experience:

Dr. Nath is presently serving as a Research Scientist at the Atal Bihari Vajpayee Regional Cancer Centre, Tripura, since April 2020, where he conducts pivotal research on postoperative outcomes and interventions in oral cancer patients. Previously, he worked as a Research Associate at the College of Fisheries, Central Agricultural University, Tripura (2018–2019), contributing to institutional-level biotech projects. In 2017–2018, he served as a Molecular Scientist and Quality Manager at Agility Diagnostics Pvt. Ltd., Delhi, a NABL-accredited molecular diagnostics lab, where he gained valuable experience in molecular testing and lab quality control. With over 13 years of interdisciplinary experience, Dr. Nath has successfully combined clinical and molecular biology expertise, making impactful contributions to oncology, diagnostics, and public health. His adaptability across academic, clinical, and industry environments illustrates his wide-ranging capabilities as a biomedical researcher and project leader.

Awards and Honors:

While specific named awards are not listed in the provided resume, Dr. Sukanta Nath’s contributions have earned peer recognition through frequent lead and co-author roles in high-impact publications. His ongoing collaboration with clinicians, epidemiologists, and nursing researchers has positioned him as a sought-after expert in cancer-related intervention studies in North-East India. He has been an instrumental figure in pioneering randomized clinical studies assessing fatigue, anxiety, and quality of life in post-surgical oral cancer patients—work that has been accepted in internationally indexed journals. His contributions to the molecular epidemiology of HPV in Indian women also reflect national relevance. The volume and scope of his work, alongside a sustained publication record, underline a distinguished career in translational cancer research. Nomination for the Distinguished Scientist Award is a well-aligned recognition of his achievements and continued potential to contribute at the national level.

Research Focus:

Dr. Nath’s primary research interest lies in molecular biology, oncology, and virology, with a strong emphasis on translational studies that impact patient care. He has led intervention-based research evaluating the role of nursing and clinical protocols in improving postoperative recovery among oral cancer patients. His work assesses anxiety, fatigue, and quality of life post-surgery using evidence-based methodologies. Dr. Nath has also contributed significantly to molecular epidemiology, particularly studying the distribution of high-risk HPV genotypes among women in North-East India. His experience in diagnostics and biotech allows him to approach clinical problems from both biomedical and molecular perspectives, making his research integrative and impactful. The focus on nursing intervention studies, rarely explored in Indian cancer centers, demonstrates his commitment to holistic cancer care. His future goals involve scaling such studies to wider patient populations and contributing to national cancer care protocols.

Publications Top Notes:

  1. 📘 Effectiveness of a supportive educational intervention on pain and physical function among patients undergone abdominal surgery: A randomized controlled trial

  2. 📗 Effectiveness of comprehensive nursing intervention on alleviating postoperative fatigue and anxiety in patients with oral cancer

  3. 📕 Molecular epidemiology and genotype distribution of genital high-risk human papillomavirus among women in North–East India

  4. 📙 Effectiveness of Nursing Interventions on Anxiety among Postoperative Oral Cancer Patients in Regional Cancer Centre, Tripura

  5. 📒 Importance of Nursing Intervention in Alleviating Post-Surgical Fatigue for Patients with Oral Cancer

  6. 📓 Does comprehensive nursing intervention improve post-surgical anxiety in patients with oral cancer?

  7. 📔 Post-Surgical Evaluation of Quality of Life in Patients with Oral Cancer: An Intervention Study from India

  8. 📚 Assessment of Fatigue and Quality of Life amongst Post-Operative Oral Cancer Patients: A Randomized Case Control Study

  9. 📙 Effect of Comprehensive Nursing Intervention on Anxiety and Quality of Life in Postoperative Patients with Oral Cancer

  10. 📗 Prognosis and Treatment in Acute Myeloid Leukemia: A Comprehensive Review

Conclusion:

Dr. Sukanta Nath has demonstrated dedicated service, innovative research, and strong scientific output in the fields of molecular biology and oncology, particularly with a patient-centric approach to oral cancer care. His work addresses a critical healthcare challenge in North-East India and proposes practical solutions backed by rigorous research methodologies.

 

Athok Maarif | SARS-CoV-2 Infection | Best Researcher Award

Published on by Cell Biologist

Mr. Athok Maarif | SARS-CoV-2 Infection | Best Researcher Award

Mr. Athok Maarif, Tottori University, Japan

Athok Shofiudin Maarif is an emerging infectious disease researcher currently pursuing a PhD at the Graduate School of Medical Sciences, Tottori University, Japan. With a foundational background in medicine from Sebelas Maret University, Indonesia, Athok has developed a unique blend of clinical insight and advanced research capabilities. His work spans virology, immunology, microbiology, and antimicrobial resistance. He has co-authored several high-impact publications addressing timely global health challenges, particularly related to COVID-19. Athok is skilled in next-generation sequencing, viral culture, qRT-PCR, and flow cytometry, and he has hands-on experience in BSL-3 environments. He is recognized for his ability to bridge research with public health, earning multiple accolades and fellowships for his contributions to infectious disease control. His cross-cultural collaborations and commitment to translational research mark him as a promising leader in global health research.

Publication Profile: 

Orcid

Scopus

✅ Strengths for the Award:

  1. High-Impact Research Publications:

    • Athok has authored and co-authored peer-reviewed papers in reputable journals such as Frontiers in Immunology, International Journal of Molecular Sciences, Yonago Acta Medica, and Journal of Infection and Chemotherapy.

    • His work is cutting-edge, addressing SARS-CoV-2 viral persistence, immune dynamics during Omicron, and microbiome analysis using next-generation sequencing.

  2. Technical Proficiency:

    • Mastery in NGS, qRT-PCR, flow cytometry, BSL-3 practices, and microbial DNA/RNA extraction.

    • Conducts complex lab work involving viral assays, PBMC isolation, and genomic studies, giving him versatility in laboratory-based infectious disease research.

  3. Strong International and Interdisciplinary Experience:

    • Research assistant roles in both Indonesia and Japan, combining clinical data, molecular science, and public health.

    • Recognized through fellowships and awards by USAID, INDOHUN, and international programs in Vietnam, Thailand, and Japan.

  4. Public Health & Global Health Perspective:

    • Active in One Health programs and waterborne disease prevention, showing ability to translate science into community impact.

    • Leads projects bridging microbiological research with real-world health policy and outreach.

⚙️ Areas for Improvement:

  1. Principal Investigator Role & Independent Research:

    • While he is a key contributor to multiple projects, Athok should aim to lead projects independently (e.g., as first or corresponding author in more papers).

    • Gaining competitive research grants or funding independently would strengthen his research autonomy.

  2. Broaden Beyond SARS-CoV-2:

    • His current research is primarily focused on COVID-19 and related microbiota studies.

    • Expanding into other emerging infectious diseases or antimicrobial resistance pathogens could widen his impact and relevance long-term.

  3. Increase Public and Policy Engagement Outputs:

    • While his research connects to public health, policy briefs, community health publications, or open-access science communication pieces would enhance visibility.

🎓 Education:

Athok Shofiudin Maarif is a PhD candidate in the Infectious Disease Department at the Faculty of Medicine, Tottori University, Japan, where he is expected to graduate in September 2025. His doctoral research focuses on the host-virus interface and antimicrobial resistance, utilizing cutting-edge genomic technologies. He previously earned his medical degree from Sebelas Maret University, Surakarta, Indonesia, graduating in April 2019. His education has emphasized both clinical medicine and research methodology, enabling him to tackle real-world infectious disease issues with scientific rigor. His early exposure to international academic programs, such as internships and short courses in Japan, Vietnam, and Thailand, enriched his global perspective and research aptitude. This educational foundation supports his current success in producing high-impact publications and executing interdisciplinary projects within both clinical and laboratory settings, further validating his dedication to global infectious disease control and scientific discovery.

💼 Professional Experience:

Athok Shofiudin Maarif has diverse experience in both research and field-based public health programs. Since 2021, he has worked as a Research Assistant in the Infectious Disease Department at Tottori University, Japan, where he manages experimental protocols, clinical sample data, and lab logistics involving pathogens at BSL-2/BSL-3 levels. His contributions include data analysis, coordination of laboratory workflow, and execution of molecular diagnostics such as qRT-PCR and viral assays. From 2018 to 2020, he served as a Research Assistant in the Public Health Department at Sebelas Maret University, organizing collaborative projects with government and health organizations in Indonesia. His interdisciplinary roles bridge laboratory and community-based research, underlining his capacity to integrate policy, education, and science in infectious disease management. This hybrid skillset enables him to effectively contribute to global health innovations and strengthens his candidacy for international research honors.

🏅 Awards & Honors:

Athok has received numerous prestigious awards that reflect both his scientific aptitude and social leadership. In 2019, he was named Best Participant in the International Short Course on Ecosystem One-Health in Thailand. He interned at Tottori University’s Infectious Disease Department in 2018 and earned the Best Project Award from USAID-INDOHUN for a community-based waterborne disease initiative. His cross-border engagements include a project on HIV/AIDS awareness for youth in Vietnam and a Research Fellowship under Sebelas Maret University’s Global Challenge Program. Earlier, in 2016, he was awarded Best Oral Presenter at a national HIV-AIDS educational program and recognized in a USAID disease outbreak preparedness course. These accolades showcase his leadership, international collaboration, and dedication to health innovation. His capacity to deliver results in both academic and field environments reflects his strength as a well-rounded researcher and strong candidate for the Best Researcher Award.

🔬 Research Focus:

Athok’s research centers on infectious diseases, particularly at the intersection of virology, immunology, and antimicrobial resistance. His PhD explores host–virus interactions in persistent SARS-CoV-2 infections, including viral evolution and gene expression profiling. He is also investigating the dynamics of natural killer cells during the Omicron phase, providing insights into immune responses. His broader work encompasses the impact of antibiotics like lascufloxacin on gut microbiota, development of rapid PCR diagnostics for COVID-19, and a systematic meta-analysis of antimicrobial resistance trends in Indonesia (2000–2023). He is also comparing resistant bacteria’s genetic profiles between Japan and Indonesia. Athok applies advanced technologies such as next-generation sequencing, flow cytometry, and BSL-3 viral culture techniques to tackle complex microbiological questions. His interdisciplinary, cross-national research approach aims to contribute practical solutions for infectious disease diagnostics, treatment, and public health strategy.

📚 Publications Top Notes:

  1. 🦠 Host–Virus Interface in Persistent SARS-CoV-2 Infections: Viral Characteristic Evolution and Gene Expression Profiling Analysis

  2. 🧪 Distinct Immunity Dynamics of Natural Killer Cells in Mild and Moderate COVID-19 Cases During the Omicron Variant Phase

  3. 🧬 Temporal Effects of Lascufloxacin on Human Gut and Salivary Microbiota: Analysis Using Next-Generation Sequencing Method

  4. 🧫 An Optimal Transport Medium for SARS-CoV-2 Detection in the Direct Method of Rapid Microfluidic PCR System

  5. 💊 Antimicrobial Resistance Trends in Indonesia (2000–2023): A Systematic Review and Meta-Analysis of Bacterial Resistance Across Antibiotic Classes (under review)

  6. 🧻 Comparison of Antimicrobial Resistance Characteristics and Genetic Profiles of Resistant Bacteria in Japan and Indonesia (ongoing)

📝 Conclusion:

Athok Shofiudin Maarif is an exceptionally promising early-career researcher in the field of infectious diseases. His strong international publication record, lab proficiency, and engagement in One Health initiatives make him highly suitable for the Best Researcher Award. His trajectory demonstrates significant leadership potential in translational virology and public health. With further development in grant leadership and broader disease focus, he will continue to emerge as a top-tier researcher in global infectious diseases.

Yuxiang Wang | Molecular Biology | Best Researcher Award

Published on by Cell Biologist

Dr. Yuxiang Wang | Molecular Biology | Best Researcher Award

Dr. Yuxiang Wang, Fudan University, China

Dr. Yuxiang Wang is a Principal Investigator and Ph.D. Supervisor at Fudan University, with an extensive background in molecular biology, oncology, and translational medicine. He earned his Ph.D. in Developmental and Molecular Biology from the Albert Einstein College of Medicine, where he worked under the mentorship of Dr. Jeffrey W. Pollard. Following this, he completed a prestigious research fellowship at Memorial Sloan-Kettering Cancer Center. Dr. Wang has built a strong academic and clinical research portfolio, focusing on gliomas and muscular dystrophy. His work utilizes state-of-the-art preclinical models and CRISPR screening technologies to identify novel therapeutic strategies. Dr. Wang is a recipient of numerous honors, including the MSK Society Scholar Award and Shanghai Leading Overseas Talent recognition. He actively collaborates with clinicians to translate lab discoveries into patient therapies, and his prolific publication record reflects deep scientific rigor and innovation.

Publication Profile: 

Scopus

✅ Strengths for the Award:

  1. Strong Research Track Record
    Dr. Wang has published in top-tier journals such as Nature Communications, Science Advances, Cancer Research, and PNAS. His publication record demonstrates consistency, depth, and high impact across multiple domains including glioma biology and gene therapy.

  2. Dual Research Focus
    He leads research in two distinct yet critical biomedical areas—malignant gliomas and muscular dystrophy. This breadth shows versatility and the ability to manage complex translational programs.

  3. Innovative Techniques
    Dr. Wang effectively applies CRISPR-based genetic screening, preclinical mouse models, and patient-derived cell lines—cutting-edge tools that reflect a forward-thinking, high-tech research approach.

  4. International Research Background
    His training and professional experience in both the U.S. (at Memorial Sloan-Kettering Cancer Center) and China make him a bridge between Western and Eastern biomedical research ecosystems.

  5. Leadership and Mentorship
    Serving as both Principal Investigator and Ph.D. Supervisor, and having been Vice Director at a major clinical research center, Dr. Wang shows strong leadership and a commitment to research training.

  6. Recognitions and Awards
    Prestigious honors such as the Shanghai Leading Overseas Talent, Shanghai Pujiang Talent, and MSK Society Scholar Award (twice) underline peer recognition and scientific excellence.

🛠️ Areas for Improvement:

  1. Clinical Translation and Implementation
    While his preclinical work is strong, more details or evidence on how these findings have progressed toward clinical trials or therapeutic products could further strengthen his translational profile.

  2. Interdisciplinary Collaborations
    Expanding collaborations across fields like bioengineering, immunotherapy, or computational biology may add further value and broaden research impact.

  3. Visibility and Outreach
    Increasing visibility through keynote lectures, patents, or public datasets could enhance his reputation globally and support broader dissemination of his work.

  4. Grants and Funding Portfolio
    While not detailed in the CV, highlighting national/international grant leadership or participation would provide insight into his ability to secure and manage competitive research funding.

🎓 Education:

Dr. Yuxiang Wang holds a distinguished academic background across leading institutions. He completed his Ph.D. in Developmental and Molecular Biology at Albert Einstein College of Medicine (2008–2014), under Dr. Jeffrey W. Pollard, focusing on hormone signaling and uterine biology. Before that, he earned a Master of Sciences from Fudan University (2004–2007), mentored by Dr. Bo Chen, where he explored hormone interactions in reproductive biology. He began his academic journey with a Bachelor of Sciences from the Ocean University of China (2000–2004), majoring in life sciences. This robust education laid the foundation for his later success in cancer biology and translational research. Throughout his academic path, Dr. Wang has demonstrated a consistent focus on the cellular and molecular mechanisms underlying human diseases, especially cancer and genetic disorders. His education, blending rigorous laboratory work and clinical relevance, has uniquely positioned him for cutting-edge biomedical research.

💼 Experience:

Dr. Wang currently serves as Principal Investigator and Ph.D. Supervisor at Fudan University’s School of Basic Medical Sciences (2020–present), where he leads research on gliomas and muscular dystrophy. From 2021 to 2023, he also held the position of Vice Director of the Research Department at the Clinical Research Center of the Affiliated Children’s Hospital of Fudan University, coordinating clinical and translational projects. Prior to his return to China, Dr. Wang worked as a Research Fellow at Memorial Sloan-Kettering Cancer Center (2015–2020), collaborating with Dr. Timothy Chan and Dr. Jason Huse on the molecular basis of brain tumors and treatment resistance. His career bridges fundamental science and clinical applications, with a focus on leveraging genetic models and CRISPR technologies to uncover therapeutic targets. Dr. Wang’s international experience and leadership in high-impact research programs underscore his contributions to biomedical innovation and mentorship.

🏅 Awards and Honors:

Dr. Yuxiang Wang’s outstanding scientific contributions have been recognized through several prestigious awards. He was named a Shanghai Leading Overseas Talent (2020) and a Shanghai Pujiang Talent (2020), highlighting his excellence in international scientific exchange and leadership. While at Memorial Sloan-Kettering Cancer Center, he was twice awarded the MSK Society Scholar Award (2018, 2019), which recognizes exceptional postdoctoral researchers demonstrating strong potential for independent academic careers. These accolades underscore Dr. Wang’s commitment to impactful research, innovation in therapeutic development, and mentorship of young scientists. His ability to translate fundamental research into preclinical and potentially clinical solutions sets him apart as a research leader. These honors reflect peer recognition of both the depth and translational potential of his work in oncology and genetic diseases.

🔬 Research Focus:

Dr. Wang’s research centers on two critical areas: malignant gliomas and muscular dystrophy. In glioma studies, his team investigates the cooperative role of IDH and ATRX mutations using CRISPR-based genetic screening in mouse models to identify synthetic lethal targets—genes whose inhibition can selectively kill tumor cells with specific mutations. This strategy opens doors to novel, mutation-specific therapies with minimal harm to healthy cells. In muscular dystrophy, Dr. Wang focuses on rare genetic mutations affecting glycosylation pathways, utilizing patient-derived cells and animal models to evaluate gene therapy and genome editing solutions. His work seeks not only to understand disease mechanisms but also to bridge the lab-to-clinic gap. A long-term objective is to offer personalized therapies for patients with genetically defined diseases. The integration of molecular biology, translational research, and therapeutic innovation defines his approach.

📚 Publication Top Notes: 

  1. 🧬 Genetically Engineered Mouse Models Unveil Mechanisms and Therapeutic Strategies for GMPPB-Associated Dystroglycanopathy – Nature Communications (under revision)

  2. 🧠 PRICKLE4 Underlies IDH mutant Tumor Resistance against PARP Inhibition – Advanced Science (under revision)

  3. 🧫 Comprehensively characterizing eRNA in immune cells to screen combinational strategies for anti-cancer immunotherapy – Cancer Research (2025)

  4. 🔬 Targeting therapeutic vulnerabilities with PARP inhibition and radiation in IDH-mutant gliomas and cholangiocarcinomas – Science Advances

  5. 🧬 G-quadruplex DNA drives genomic instability and represents a targetable molecular abnormality in ATRX-deficient malignant glioma – Nature Communications

  6. 🧪 Mutant-IDH1-dependent chromatin state reprogramming, reversibility, and persistence – Nature Genetics

  7. 🧠 Atrx inactivation drives disease-defining phenotypes in glioma cells of origin through global epigenomic remodeling – Nature Communications

  8. 🧬 Activation of protein synthesis in mouse uterine epithelial cells by estradiol-17β is mediated by a PKC–ERK1/2–mTOR signaling pathway – PNAS

  9. 🔬 GSK-3β mediates in the progesterone inhibition of estrogen-induced cyclin D2 nuclear localization and cell proliferation in cyclin D1−/− mouse uterine epithelium – FEBS Letters

🧾 Conclusion:

Dr. Yuxiang Wang is a highly deserving candidate for the Best Researcher Award. He demonstrates:

  • A clear and sustained record of scientific excellence,

  • Deep expertise in cancer biology and rare disease genetics,

  • Use of innovative methodologies, and

  • Leadership in both academic and clinical research environments.

His contributions to understanding the molecular basis of gliomas and developing targeted therapies for muscular dystrophy have significant implications for personalized medicine. With continued development in clinical translation and interdisciplinary reach, he stands out as a leader of the next generation of biomedical scientists.

Zhaowei Feng | Stem Cell Research | Best Researcher Award

Published on by Cell Biologist

Dr. Zhaowei Feng | Stem Cell Research | Best Researcher Award

Dr. Zhaowei Feng, The Second Affiliated Hospital of Xuzhou Medical University, China

Zhaowei Feng is a dedicated biomedical researcher specializing in neurobiology and pharmacology, currently serving as an Assistant Researcher at The Second Affiliated Hospital of Xuzhou Medical University. With a solid academic foundation and a passion for neuroscience, Feng has made significant contributions to understanding mechanisms of neuroprotection and demyelination. His research spans neurodegenerative disease models such as multiple sclerosis and neonatal hypoxia-ischemia, utilizing molecular and cellular biology tools. Known for his collaborative nature and scientific rigor, Feng has co-authored multiple peer-reviewed articles in prestigious journals and has played pivotal roles in various national and municipal-level research projects. He is particularly recognized for co-first authorship in several studies, reflecting leadership in experimental design and data analysis. His growing influence in the field is further supported by ongoing funded projects and a research trajectory aimed at translational outcomes. Feng is committed to continuing impactful research that bridges bench science with clinical applications.

Publication Profile:

Scopus

✅ Strengths for the Award:

  1. Strong Research Focus in Neurobiology 🧠
    Zhaowei Feng has a consistent and impactful research portfolio in neurobiology, particularly in myelination, ischemia-reperfusion injury, and glutamate signaling. His work is highly relevant in addressing diseases like multiple sclerosis and neonatal hypoxia-ischemia encephalopathy.

  2. Publications in High-Impact Journals 📚
    He has co-authored several peer-reviewed journal articles in reputable journals such as Phytomedicine, Pharmacology, Oncology Reports, and Frontiers. His contributions as co-first author in multiple papers reflect significant involvement in study design and experimentation.

  3. Independent Researcher Role 🧪
    He currently serves as a Principal Investigator for a municipal-level research project funded by the Xuzhou Health Commission, demonstrating trust in his leadership and research direction.

  4. Multidisciplinary Expertise 🔬
    His research integrates pharmacology, molecular biology, and neuroscience, covering diverse mechanisms like PPARγ signaling, SUMOylation, and ferroptosis, which enhances translational potential.

  5. Rapid Academic Growth 🚀
    Transitioning quickly from a Master’s student (2019–2022) to Assistant Researcher and PI (since 2022) shows a fast-tracked academic trajectory.

⚠️ Areas for Improvement:

  1. Need for More First-Author and Corresponding-Author Papers ✍️
    While co-first authorship is commendable, a stronger emphasis on sole first or corresponding authorship in future publications would establish more scientific independence.

  2. Limited Recognition at National Level 🏅
    Most current funding and achievements are at the municipal level. Applying for national or international grants (e.g., NSFC, NIH) would elevate his research profile.

  3. Postdoctoral Training or Collaboration Abroad 🌍
    Gaining international experience or collaborating with global research centers could broaden perspectives and techniques, increasing citation impact and networking.

  4. More Diversified Research Outputs 📊
    Exploring patents, clinical trials, or translational research outcomes could further demonstrate innovation and application potential.

🎓 Education:

Zhaowei Feng began his academic journey in the biological sciences at Xuzhou Medical University, where he earned his Bachelor’s degree between 2014 and 2018. He further pursued a Master’s degree in Neurobiology at the same institution from September 2019 to July 2022. His graduate studies were marked by an intensive focus on neurodegenerative mechanisms, including demyelination and neuroinflammation, with particular attention to cuprizone-induced and ischemia-reperfusion mouse models. His research also explored glutamate transport regulation, the PPARγ pathway, and oligodendrocyte differentiation. His educational foundation not only provided him with technical proficiency in experimental neuroscience but also cultivated a strong understanding of translational biomedical research. Through rigorous coursework, laboratory experience, and thesis writing, Feng developed a robust academic profile that seamlessly transitioned into his research career. His educational journey reflects consistent dedication and a clear trajectory towards clinical and experimental neurobiology.

🧪 Experience:

Since September 2022, Zhaowei Feng has been working as an Assistant Researcher at The Second Affiliated Hospital of Xuzhou Medical University. His role involves leading preclinical studies, managing collaborative projects, and mentoring junior researchers. Feng has also served as Principal Investigator on a municipal-level research grant focusing on blood-brain barrier damage post-transplantation. He actively participates in multiple interdisciplinary studies involving neurodevelopment, myelination, and pharmacological interventions. Prior to his current role, his Master’s research provided hands-on experience with animal models, molecular techniques, and data analysis in neurobiology. Feng has authored or co-authored numerous research papers, some as co-first author, contributing significantly to study design and execution. He is also involved in translational research projects that aim to bridge laboratory findings with clinical therapies. His work ethic, attention to detail, and innovative approach make him a valuable contributor to the field of neurobiological research.

🏅 Awards and Honors:

Zhaowei Feng has been recognized for his scientific contributions through both academic and research-oriented accolades. Notably, he is the recipient of a research grant from the Xuzhou Municipal Health Commission (Project No. XWKYHT20230029), focusing on cerebral ischemia-reperfusion and blood-brain barrier injury. Though early in his professional career, his selection as Principal Investigator on this project signifies trust in his leadership and expertise. Several of his publications in high-impact journals list him as co-first author—an honor that highlights his equal contribution in rigorous experimental work. While he has yet to receive national awards such as from the Natural Science Foundation, his steady academic output and funded research projects mark a strong trajectory. His growing publication record and role in significant studies position him as a rising talent in the biomedical field. Future honors are likely as his research continues to address key questions in neuroscience and pharmacology.

🔬 Research Focus:

Zhaowei Feng’s research centers on neuroprotection, demyelination, and neuroinflammation, with a particular focus on the mechanisms underlying multiple sclerosis, ischemic brain injury, and neonatal encephalopathy. His studies often employ animal models such as cuprizone-induced demyelination and hypoxia-ischemia to explore therapeutic targets. Feng is particularly interested in the regulation of oligodendrocyte differentiation and the role of glutamate transporters, signaling molecules like PPARγ, and pathways involving Wnt/β-catenin and SUMOylation. Additionally, he has investigated compounds such as diosgenin and alpha-asaronol for their neuroprotective and remyelination-promoting effects. His work also extends into cancer biology, with studies on ferroptosis and protein regulation in squamous cell carcinoma. By integrating molecular biology, pharmacology, and neurodevelopmental research, Feng aims to contribute to the discovery of new treatments for central nervous system disorders. His current and future research is geared toward translational medicine that bridges laboratory science with clinical applications.

📚 Publication Top Notes:

  1. 🧠 Alpha-Asaronol Alleviates Dysmyelination by Enhancing Glutamate Transport via PPARγ-GLT-1 Signaling in Neonatal Hypoxia-Ischemia (Pharmacology, 2022)

  2. 🧬 C1q Inhibits Differentiation of Oligodendrocyte Progenitor Cells via Wnt/β-Catenin Signaling (Biomedicine & Pharmacotherapy, 2023)

  3. 🧪 Alpha-Asaronol Promoted OPC Differentiation and Improved Myelination as a PPARγ Activator (Frontiers, 2023)

  4. 🧫 Diosgenin Promoted OPC Differentiation by Blocking GLUR2/GAPDH Interaction in Pilocarpine-Induced Epilepsy Rats (Phytomedicine, 2025)

  5. 🧬 Netrin-4 Mediates Piezo1 Inactivation and YAP Signaling Alleviation in Cerebral Ischemia-Reperfusion (Oncology Reports)

  6. 🔬 SENP1 Inhibits Ferroptosis and Promotes Head and Neck Squamous Cell Carcinoma by Regulating ACSL4 Protein (Molecular Oncology, 2023)

  7. 🧪 SUMO1-Mediated Stabilization Enhances Protein Function in Neuroinflammatory Models (Unspecified Journal)

  8. 🧠 Signaling Activation in a Cuprizone-Induced Mouse Model of Multiple Sclerosis (Unspecified Journal)

📌 Conclusion:

Zhaowei Feng is a highly promising early-career researcher with a clear scientific focus, a growing publication record, and demonstrated ability to lead independent research. His work addresses critical challenges in neurobiology and pharmacology, making a tangible impact in both experimental and translational medicine. With continued progression—especially toward national-level recognition and senior authorship—he has the potential to become a leader in his field.

ALINE TAKEJIMA | Tissue engineering | Women Researcher Award

Published on by Cell Biologist

Dr. ALINE TAKEJIMA | tissue engineering | Women Researcher Award

Dr. ALINE TAKEJIMA, pontificia universidade catolica do parana, Brazil

Dr. Aline Luri Takejima is a physician-scientist from Brazil, specializing in regenerative medicine and wound healing. She holds an MD and a PhD in Health Sciences from the Pontifical Catholic University of Paraná (PUCPR), where she currently conducts postdoctoral research. With a focus on biological therapies involving the amniotic membrane, Wharton’s jelly, and mononuclear stem cells, Dr. Takejima has published in multiple high-impact scientific journals. Her research aims to develop novel regenerative strategies to treat complex wounds and enhance tissue repair. As an active member of PUCPR’s Wound Healing Research Group and the Brazilian Society of Plastic Surgery, she combines scientific rigor with clinical insight to bridge bench-to-bedside innovation. Her academic contributions are guided by a translational approach, offering promising avenues for future clinical applications in tissue engineering.

Publication Profile: 

Orcid

✅ Strengths for the Award:

  1. Focused Research Excellence:
    Dr. Takejima’s work on biological scaffolds and stem cells in wound healing is both innovative and clinically relevant. Her studies using amniotic membrane, Wharton’s jelly, and bone marrow mononuclear cells show promising regenerative outcomes in preclinical models.

  2. Research Productivity:
    With 9 peer-reviewed journal articles in high-quality platforms (e.g., Biomedicines, Tissue Barriers, Annals of Biomedical Engineering), she demonstrates consistent academic output in her field.

  3. Translational Impact:
    Her research bridges basic science and clinical practice, aiming to provide regenerative solutions for patients with chronic wounds and cardiac damage.

  4. Collaborative Engagement:
    Active participation in a multidisciplinary wound healing research group, contributing to cross-functional scientific advancements.

  5. Recognition Potential:
    As a young, emerging woman researcher in biomedical sciences, she stands as a role model for future female scientists in Latin America and beyond.

🔧 Areas for Improvement:

  1. Intellectual Property & Innovation:
    No patents filed yet; transitioning her research into patentable therapies or commercial applications would increase its societal and economic impact.

  2. Leadership Roles:
    While active in research, taking on editorial or scientific leadership positions would enhance her academic visibility and influence.

  3. Internationalization:
    She would benefit from developing international collaborations or fellowships to diversify her research scope and increase global reach.

  4. Industry Engagement:
    Engaging in consultancy or biotech partnerships can further the translational impact of her regenerative strategies.

🎓 Education:

Dr. Takejima’s educational journey began with a Doctor of Medicine (MD) degree from the Pontifical Catholic University of Paraná (PUCPR), Brazil. Her passion for research led her to pursue a Doctorate (PhD) in Health Sciences/Medicine, also at PUCPR. Her doctoral thesis focused on the use of biologically active materials such as the amniotic membrane and stem cells to enhance wound healing. Throughout her academic training, she demonstrated a strong commitment to translational medicine by integrating basic science with clinical practice. During her PhD, she engaged in experimental models involving stem cell therapy and tissue engineering, which laid the groundwork for her current postdoctoral research. Her educational path reflects both depth and specialization in the biomedical sciences, particularly in regenerative medicine and cellular therapies.

💼 Experience:

Dr. Aline Takejima has over a decade of experience in medical and scientific fields, balancing her role as a physician with that of a postdoctoral researcher. Her clinical background informs her research, particularly in areas of wound healing and regenerative medicine. At PUCPR, she contributes to the Wound Healing Research Group, where she is involved in designing and conducting animal model studies to test the effects of biomaterials and stem cells. Her multidisciplinary research integrates immunology, histopathology, and molecular biology. With nine peer-reviewed publications and participation in collaborative research, she has become a respected contributor to the field. Though early in her research career, her trajectory shows a steady rise, marked by evidence-based outcomes and a commitment to innovation. Her goal is to bridge clinical challenges with regenerative solutions that can be implemented in real-world medical practice.

🔬 Research Focus:

Dr. Takejima’s research focuses on regenerative strategies for wound healing, utilizing biomaterials and stem cells. Her work primarily explores the application of amniotic membrane, Wharton’s jelly, and bone marrow-derived mononuclear stem cells in treating complex or chronic skin wounds. Using experimental models in rats and rabbits, she evaluates histological recovery, inflammation modulation, and tissue regeneration. A significant aspect of her research is understanding how these materials promote healing through paracrine effects rather than direct integration, offering a safer and scalable pathway to clinical application. Additionally, her work extends to cardiac and tracheal tissue repair, emphasizing the versatility of these regenerative approaches. The translational nature of her research bridges laboratory discoveries with potential bedside applications, positioning her at the forefront of cellular therapy and biomaterials science.

📚 Publications Top Notes:

  1. 🧠 Wharton’s Jelly Bioscaffolds Improve Cardiac Repair with Bone Marrow Mononuclear Stem Cells in Rats – Journal of Functional Biomaterials, 2025

  2. 🧫 The effects of decellularized amniotic membrane and Wharton’s jelly on the healing of experimental skin wounds in rats – Tissue Barriers, 2025

  3. ❤️ Bone-marrow mononuclear cells and acellular human amniotic membrane improve global cardiac function… – Anais da Academia Brasileira de Ciências, 2024

  4. 🫁 Tracheal regeneration with acellular human amniotic membrane and 15d-PGJ2 nanoparticles in rabbits – Anais da Academia Brasileira de Ciências, 2023

  5. 🧬 Acellular Biomaterials + Autologous Stem Cells Improve Wound Healing via Paracrine Effects – Biomedicines, 2023

  6. 💉 Decellularized Amniotic Membrane Solubilized with Hyaluronic Acid in Wound Healing – Annals of Biomedical Engineering, 2022

  7. 🧪 Role of Mononuclear Stem Cells and Decellularized Amniotic Membrane in Skin Wounds – Tissue Barriers, 2022

  8. 🏥 Trauma hepático: epidemiologia de cinco anos… – Revista do Colégio Brasileiro de Cirurgiões, 2008

🧾 Conclusion:

Dr. Aline Luri Takejima is an outstanding candidate for the Women Researcher Award. Her academic profile demonstrates a strong foundation in regenerative medicine with significant contributions to wound healing research. Her commitment to applying biological therapies in clinical contexts shows both depth and innovation. As a woman scientist in a competitive field, she exemplifies leadership, dedication, and potential. With further growth in global engagement and innovation strategy, Dr. Takejima is poised to become a future leader in regenerative biomedical research.

HEMAMALINI MADHUKAR | Cancer Cell Biology | Best Researcher Award

Published on by Cell Biologist

Dr. HEMAMALINI MADHUKAR | Cancer Cell Biology | Best Researcher Award

Dr. HEMAMALINI MADHUKAR, Mother Teresa Women’s University, India

Dr. Madhukar Hemamalini is an accomplished Assistant Professor in the Department of Chemistry at Mother Teresa Women’s University, Kodaikanal. With over five and a half years of dedicated research experience and eight years of teaching, she has made significant contributions to the field of structural and bioorganic chemistry. Her expertise lies in X-ray crystallography, protein-ligand interactions, and the synthesis of supramolecular and pharmaceutical compounds. She earned her Ph.D. in Chemistry from Bharathidasan University and completed a postdoctoral fellowship under Prof. H.-K. Fun at Universiti Sains Malaysia. With 234 international publications and a citation index reflecting her research impact, Dr. Hemamalini’s academic presence is both global and influential. Her guidance to 10 M.Phil. and 21 M.Sc. students reflects her commitment to mentoring the next generation of scientists. She actively contributes to academic committees and has led a UGC Minor Research Project on hydrogen bonding and phase transition.

Publication Profile: 

Scopus

✅ Strengths for the Award:

  1. Extensive Publication Record

    • Over 234 international research publications, primarily in reputed journals such as Journal of Molecular Structure, Molecular Diversity, Russian Journal of Inorganic Chemistry, and IUCrData.

    • Research themes include X-ray crystallography, drug-likeness prediction, molecular docking, and biochemical analysis.

  2. Strong Research Background

    • Postdoctoral research in crystallography at Universiti Sains Malaysia (USM) under a globally respected crystallographer, Prof. H.-K. Fun.

    • More than five and a half years of focused research experience in supramolecular and macromolecular chemistry.

  3. Citation Impact

    • Accumulated 228 citations, with a h-index of 12 and i10-index of 8, reflecting a solid impact in her field.

  4. Mentorship & Teaching

    • 8 years of teaching experience as an Assistant Professor.

    • Mentored 10 M.Phil. and 21 M.Sc. students — demonstrating her commitment to research training and knowledge dissemination.

  5. Research Funding

    • Successfully secured UGC Minor Research Project funding of ₹5,00,000 for studies on hydrogen bonding and phase transition.

  6. Academic Service

    • Contributed to institutional growth as inspection committee member for women’s colleges, affirming leadership in academic governance.

⚠️ Areas for Improvement:

  1. Enhance International Collaboration

    • Collaborations beyond Malaysia, particularly with Europe or North America, could increase citation visibility and interdisciplinary reach.

  2. Diversify Funding Sources

    • Apply for major national/international grants (e.g., DST, DBT, SERB, or industry-academic partnerships) for scaling research infrastructure and student involvement.

  3. Intellectual Property & Innovation

    • Translating research into patents, prototypes, or industry consultancies would enhance her research’s practical value and real-world impact.

  4. Public Engagement and Outreach

    • Participation in conferences as keynote speaker, science communication, or popular science articles would further establish her academic persona.

🎓 Education:

Dr. Madhukar Hemamalini completed her Ph.D. in Chemistry in October 2006 from Bharathidasan University, India, specializing in structural and supramolecular chemistry. Her doctoral research focused on the synthesis and crystallographic analysis of organic compounds, laying a strong foundation for her future work in macromolecular systems. Prior to her doctorate, she obtained her M.Sc. in Chemistry in August 2000 and B.Sc. in Chemistry in August 1998, both from Bharathidasan University. Her academic training has equipped her with a deep understanding of chemical interactions at the molecular level, especially those relevant to drug design, protein-ligand binding, and pharmaceutical solids. Her academic trajectory showcases her longstanding passion for exploring the molecular world through advanced techniques like X-ray crystallography and computational chemistry. Additionally, her exposure to interdisciplinary research at Universiti Sains Malaysia has expanded her global outlook and enriched her research methodologies.

🧪 Experience:

Dr. Hemamalini has a cumulative 13+ years of experience in academia and research. She is currently serving as Assistant Professor at the Department of Chemistry, Mother Teresa Women’s University, Kodaikanal since March 2015. Her teaching portfolio includes mentoring postgraduate and M.Phil. students, with 21 M.Sc. and 10 M.Phil. students successfully guided under her supervision. From December 2009 to February 2012, she pursued Post-Doctoral research in X-ray crystallography at Universiti Sains Malaysia under the mentorship of Prof. H.-K. Fun, focusing on supramolecular motifs and metal coordination complexes. Her total research experience spans over five and a half years, during which she explored protein-ligand interactions, crystal engineering, and bioorganic compound synthesis. She also participated in institutional academic committees and inspection boards, contributing to higher education quality assurance. Her dual expertise in both teaching and high-impact research makes her a well-rounded academic professional.

🏆 Awards and Honors:

Dr. Madhukar Hemamalini has been the recipient of the prestigious Senior Research Fellowship (SRF) from the Council of Scientific and Industrial Research (CSIR), New Delhi (2004–2006), which stands as a testimony to her research potential and academic rigor. In addition to this major national honor, she has been involved in several university-level academic panels, including Inspection Committees for women’s colleges in Dindigul, highlighting her contributions to academic governance and quality control. Her funded project under the UGC Minor Research Project Scheme—with a sanctioned amount of ₹5,00,000—focused on the hydrogen bonding interactions and phase transition studies in organic compounds, an area of current interest in molecular chemistry. Her work has been cited over 228 times, and she holds a h-index of 12 and an i10-index of 8, reflecting a consistent and meaningful research output across international journals.

🔬 Research Focus:

Dr. Hemamalini’s research revolves around X-ray crystallography, macromolecular chemistry, and supramolecular design. Her scientific interest lies in unraveling structure–function relationships in molecules, particularly in protein-ligand complexes, bioorganic frameworks, and pharmaceutical solids. She has applied her expertise in both experimental (e.g., crystal growth and structural analysis) and computational techniques (e.g., molecular docking, dynamics simulations) to synthesize novel compounds with potential drug-like behavior. Her interdisciplinary approach bridges chemistry with biology, enabling her to work on problems like TNF-α inhibition in rheumatoid arthritis, anti-cancer screening, and antidiabetic compound design. She has actively published in reputed journals, showcasing both synthetic and theoretical studies. Her postdoctoral training at Universiti Sains Malaysia helped her master crystallographic techniques, further enriching her analytical capabilities. Her work continues to contribute valuable insights into biomolecular recognition, drug-receptor modeling, and material science.

📚 Publications Top Notes: 

  1. 📄 Synthesis of 3-Methoxy…phenol Schiff base: spectral, in-silico & in-vitro studies – Heliyon, 2022

  2. 🧬 In silico and in vitro identification of TNF-α inhibitors from Euphorbia hirta for rheumatoid arthritis – Molecular Diversity, 2025

  3. 💊 Anti-diabetic activity of pyrimidinium-hydrogen oxalate conjugates: synthesis, docking & simulation – Journal of Molecular Structure, 2025

  4. 🧪 [2-(1H-indol-3-yl)ethyl]-(4-nitrobenzylidene)amine: anti-breast cancer & antibacterial insights – Journal of Molecular Structure, 2025

  5. 🔬 PPI networking, expression analysis & TNF-α inhibitor screening for RA – Molecular Diversity, 2025

  6. 🧫 6-Bromo-9,9-diethyl-N,N-diphenylfluoren-2-amine – Data Paper

  7. 🧊 Insights into oxidovanadium porphyrin: synthesis & Hirshfeld surface analysis – Journal of Molecular Structure, 2024

  8. 🧬 1,4-Dimethylpiperazine-2,3-dione – crystal structure study – Iucrdata, 2024

  9. ⚗️ (1H-Benzodiazol-2-ylmethyl)diethylamine – molecular characterization – Iucrdata, 2024

  10. 🔍 Structural & oxidative studies of (3,4,5-trimethoxyphenyl)Porphyrin Ni(II) Complex – Russian Journal of Inorganic Chemistry, 2024

🧾 Conclusion:

Dr. Madhukar Hemamalini possesses a well-rounded academic profile with consistent research output, teaching excellence, mentorship, and academic service. Her work in structural and medicinal chemistry, particularly involving crystallography and biomolecular interactions, has practical implications in drug discovery and material science. She demonstrates all the key markers of a successful and impactful researcher.

Alaka Sahoo | Immunology Cellular Interactions | Young Researcher Award

Published on by Cell Biologist

Mrs. Alaka Sahoo | Immunology Cellular Interactions | Young Researcher Award

Mrs. Alaka Sahoo, Siksha’O’ Anusandhan University, India

Dr. Alaka Sahoo is a dedicated young researcher in the field of Biotechnology with a focus on translational and clinical research. She holds a Ph.D. in Biotechnology from Siksha ‘O’ Anusandhan University, Odisha, with a CGPA of 8.90. With over 17 publications, including 11 research articles and 3 high-impact reviews, Dr. Sahoo has significantly contributed to oral disease therapeutics and antimicrobial studies. She demonstrates expertise in multi-omics analysis, drug discovery, and natural product-based therapy. A recipient of prestigious awards such as the Lalchand Women Entrepreneurs Award (2024), she is also a life member of reputed organizations like the British Society for Antimicrobial Chemotherapy. Her innovative approach to disease management using phytochemicals and peptides sets her apart as a rising talent in biomedical research.

Publication Profile: 

Google Scholar

Scopus

Orcid

✅ Strengths for the Award:

  1. Strong Publication Record:

    • 17 publications including 11 original research, 3 reviews, and 2 book chapters, showcasing depth and breadth.

    • 7 papers as first or corresponding author—indicating independent research capability.

    • Research in high-impact journals like Frontiers in Microbiology, Journal of Ethnopharmacology, Nanomaterials, and Chemistry & Biodiversity.

  2. Innovative & Multidisciplinary Research:

    • Integrates multi-omics, computational modeling, clinical dermatology, and natural products.

    • Focus on oral inflammatory diseases, antimicrobial peptides, and drug delivery systems.

  3. Academic Excellence & Research Training:

    • Ph.D. with 8.90 CGPA, and M.Sc. with 87.07% marks.

    • Expertise in BSL-2+ lab work, PCR, ELISA, microbial culture, and molecular docking.

  4. Awards & Recognition:

    • Lalchand Women Entrepreneurs Award (2024).

    • MSME-Idea Hackathon Innovation Award, Govt. of India.

  5. Global and National Engagement:

    • Life member of the British Society for Antimicrobial Chemotherapy (UK).

    • Demonstrates leadership in science entrepreneurship and women in research.

🛠️ Areas for Improvement:

  1. Expanded International Collaboration:

    • Building long-term research partnerships with international labs could increase global visibility.

  2. Patent/Technology Transfer Efforts:

    • While publications are strong, translating research into patents or commercial products will further strengthen applied impact.

  3. Focused Project Leadership:

    • Leading large interdisciplinary projects or acquiring independent grants will showcase funding leadership.

🎓 Education:

Dr. Alaka Sahoo has pursued a progressive academic path in Biotechnology. She earned her Ph.D. in Biotechnology from the School of Pharmaceutical Sciences, Siksha ‘O’ Anusandhan Deemed University, Odisha, completing her research with a notable 8.90 CGPA. Her thesis focused on “Therapeutic Opportunities for Oral Lichen Planus: An Integrated Multi-Omics Approach to Drug Discovery” under the guidance of Prof. (Dr.) Maitreyee Panda. Prior to this, she completed her M.Sc. in Biotechnology (87.07%) from the College of Basic Science and Humanities, OUAT, Bhubaneswar in 2018 and a B.Sc. in Biotechnology with distinction (75%) from Ramadevi Women’s College, Utkal University in 2016. Her academic journey showcases a strong foundation in both theoretical and applied aspects of biosciences.

💼 Experience:

Dr. Alaka Sahoo brings rich hands-on research experience in clinical and experimental biotechnology. She is skilled in BSL-2+ lab practices, molecular techniques like PCR, gel electrophoresis, microbial culture, ELISA-based diagnostics, and bioinformatics. Her doctoral work integrated multi-omics and computational biology to study inflammatory oral diseases, and her postdoctoral research spans drug delivery and antimicrobial drug discovery. As first or corresponding author in 7 out of 17 publications, she has led collaborative studies with both national and international partners. Dr. Sahoo’s cross-disciplinary knowledge in microbiology, pharmacology, and nanomedicine enhances her problem-solving abilities, making her a versatile researcher. Her ability to bridge clinical dermatology with biotechnology research positions her as an impactful contributor in both healthcare and academic environments.

🏆 Awards & Honors:

Dr. Alaka Sahoo has received notable accolades for her innovation and leadership in science. In 2024, she was awarded the Lalchand Women Entrepreneurs Award by the Odisha Corporate Foundation, recognizing her outstanding contributions in biotech innovation. She also earned the MSME-Idea Hackathon 3.0 (Women) Innovation Award by the Government of India, honoring her practical scientific advancements with societal impact. These awards reflect her dedication to translational research and her vision to develop cost-effective, natural therapies. Dr. Sahoo is also a life member of two esteemed organizations: the British Society for Antimicrobial Chemotherapy (UK) and Bioclues Innovation, Research and Development (India). Her achievements signify her rising prominence in the field and her commitment to addressing public health challenges through integrative research.

🔬 Research Focus:

Dr. Alaka Sahoo’s research focuses on oral inflammatory diseases, natural product therapeutics, and insect-derived peptides as alternatives to conventional antimicrobials. Her Ph.D. thesis explored multi-omics approaches for drug discovery in Oral Lichen Planus, integrating in vitro, in silico, and clinical data. Her work spans immunomodulation, anti-inflammatory drug screening, and nanodrug delivery systems, with cross-functional expertise in dermatology, pharmacology, and microbiology. She combines computational modeling, molecular docking, and wet-lab validation to develop target-specific therapies. Her studies on biofilm inhibition, antifungal peptides, and phytosteroids hold promise for tackling antimicrobial resistance. Through collaborations across academia and healthcare, she aims to translate her lab findings into clinically viable solutions. Her contributions to systematic reviews and molecular simulations further demonstrate her analytical rigor and commitment to evidence-based research.

📚 Publications Top Notes:

  1. 📘 Experimental and clinical trial investigations of phytoextracts in Oral Lichen Planus: A systematic review – J Ethnopharmacol (2022)

  2. 🐞 Insect-derived antimicrobial peptides as novel anti-biofilm agents: A systematic review – Front. Microbiol. (2021)

  3. 💊 Ultraflexible liposome nanocargo for dermal drug delivery – Nanomaterials (2021)

  4. 🌿 Phytochemicals for Oral Lichen Planus: A multi-omics and experimental study – Chem Biodivers (2025)

  5. ⚗️ Carbohydrate-derived N-benzyl aminocyclopentitols with anticancer properties – Carbohydr Res. (2025)

  6. 🧬 Target-specific screening of anti-inflammatory phytosteroids using molecular docking – Steroids (2025)

  7. 🧪 Insect-derived antifungal peptides in Candida management – Int. J. Mol. Sci. (2025)

  8. 🧫 Azo-coumarin-Co(II)-galangin hybrids for multipotential activities – J. Biomol. Struct. Dyn. (2024)

  9. 🧒 Pediatric dermatology case analysis in Eastern India – Indian J. Paediatr. Dermatol. (2024)

  10. 🔬 Schiff/Mannich coumarin derivatives: Antibacterial and anti-biofilm evaluation – RSC Adv. (2024)

🧾 Conclusion:

Dr. Alaka Sahoo is highly suitable for the Research for Young Researcher Award. Her multi-disciplinary expertise, robust research record, and recognition through national awards highlight her as a promising early-career scientist. She combines academic rigor with innovation, and her work has meaningful implications for public health, especially in oral disease therapy, biofilm inhibition, and phytochemical-based drug development.

Rong Zhong | Cancer Cell Biology | Best Researcher Award

Published on by Cell Biologist

Prof. Rong Zhong | Cancer Cell Biology | Best Researcher Award

Prof. Rong Zhong, Huazhong University of Science and Technology, China

Professor Rong Zhong is an esteemed academic in the field of molecular and cancer epidemiology at Tongji Medical College, Huazhong University of Science and Technology, China. With a PhD in Epidemiology and Biostatistics and postdoctoral training from Harvard Medical School, she has built a distinguished career in investigating genetic and environmental interactions in cancer development. Over the years, she has led 51 research projects, authored 169 peer-reviewed articles, and earned over 3,600 citations. Dr. Zhong’s collaborative work extends across national and international institutions, including Huazhong Agricultural University and the General Hospital of Central Theater Command. Recognized with the Natural Science Award of Hubei Province, she is also actively involved in several national scientific committees. Her commitment to advancing cancer prevention through precision medicine and early detection strategies reflects both her scientific acumen and societal impact, making her a strong candidate for the Best Researcher Award.

Publication Profile: 

Orcid

✅ Strengths for the Award:

  1. Extensive Research Output

    • 169 SCI/Scopus-indexed publications, many in high-impact journals like Gastroenterology, Nature Reviews Clinical Oncology, and Cancer Discovery.

    • Strong citation record with 3,697 citations on Web of Science, reflecting broad scientific influence.

  2. Innovative and Impactful Research

    • Focus on molecular and cancer epidemiology, particularly gene-environment interactions in gastrointestinal cancers, addressing a critical public health challenge.

    • Groundbreaking research on environmental risk factors (e.g., bisphenol A, tobacco smoke) and genetic susceptibility in cancer risk.

  3. Grants and Funding Leadership

    • Principal investigator of major national research projects, including National Natural Science Foundation of China grants and the Young Top-notch Talent Cultivation Program of Hubei Province.

  4. Recognition and Service

    • Recipient of the Natural Science Award of Hubei Province.

    • Serves on editorial boards of reputable journals such as Ebiomedicine and American Journal of Gastroenterology.

    • Active member in national scientific committees related to cancer prevention and epidemiology.

  5. Collaboration and Mentorship

    • Strong institutional and cross-disciplinary collaborations, including with Huazhong Agricultural University and military medical research institutions.

    • A demonstrated leader in mentoring young researchers in public health and biomedical science.

⚙️ Areas for Improvement:

  1. Industry Engagement & Technology Transfer

    • Although she holds 2 patents, there is limited mention of industry consultancy or commercialization, which could strengthen real-world impact.

  2. International Policy Influence

    • Expanding her involvement in international advisory boards or global health policy initiatives could further elevate her research visibility and societal contribution.

  3. Science Communication & Public Engagement

    • Enhanced participation in public education, community outreach, or policy translation could help bridge science and society, especially in preventive oncology.

🎓 Education:

Dr. Rong Zhong earned her PhD in Epidemiology and Biostatistics from the prestigious Huazhong University of Science and Technology, where she built the foundation for her future research excellence. To further expand her academic perspective, she completed postdoctoral training at Harvard Medical School, USA—an experience that enriched her global outlook and enhanced her methodological rigor in public health research. Throughout her academic journey, Dr. Zhong has demonstrated a passion for understanding complex interactions between genes and environmental exposures, particularly in relation to cancer epidemiology. Her education, characterized by a blend of rigorous Chinese academic training and Western research exposure, has laid a strong interdisciplinary base. This robust academic background has equipped her with a unique skill set to lead impactful research in molecular epidemiology and precision prevention of gastrointestinal cancers.

💼 Experience:

Dr. Rong Zhong currently serves as a Professor at the School of Public Health, Tongji Medical College, Huazhong University of Science and Technology. With extensive experience in cancer epidemiology, she has successfully led national and provincial research initiatives including projects funded by the National Natural Science Foundation of China and the Young Top-notch Talent Cultivation Program of Hubei Province. Over the years, she has been instrumental in mentoring young scientists, shaping national health policies, and advancing cancer prevention strategies in China. She also serves on editorial boards of high-impact journals such as Ebiomedicine and American Journal of Gastroenterology. Her experience bridges research, academic leadership, and international collaboration, reflecting her multidimensional contribution to science and public health. Her advisory roles in national committees focused on cancer prevention and epidemiology further underscore her influence and thought leadership in the field.

🔬 Research Focus:

Professor Zhong’s primary research focus lies in molecular and cancer epidemiology, with an emphasis on gastrointestinal cancers. Her work aims to elucidate the gene-environment interactions that contribute to cancer risk, leveraging large-scale cohort and case-control studies. By integrating genomic data with environmental exposures (e.g., diet, pollutants, endocrine-disrupting chemicals), she develops predictive models that enable early screening and personalized prevention strategies for high-risk populations. Her recent studies investigate interactions between genetic polymorphisms and substances like bisphenol A, tobacco smoke, and gut microbiota, especially in relation to colorectal and breast cancer. These contributions bridge the gap between basic science and clinical translation, offering a pathway toward precision public health. Her research not only advances scientific knowledge but also holds tangible implications for national cancer screening guidelines and individualized preventive healthcare strategies.

📚 Publications Top Notes:

  1. 📘 Western-Style Diet, pks Island-Carrying Escherichia coli, and Colorectal Cancer: Analyses From Two Large Prospective Cohort Studies – Gastroenterology

  2. 🚬 In Utero and Childhood/Adolescence Exposure to Tobacco Smoke, Genetic Risk and Lung Cancer Incidence and Mortality in Adulthood – AJRCCM

  3. 🧬 FOXA1 of regulatory variant associated with risk of breast cancer through allele-specific enhancer in the Chinese population – Breast Cancer

  4. 🧪 Genome-wide gene-bisphenol A, F and triclosan interaction analyses on urinary oxidative stress markers – Science of The Total Environment

  5. 🧫 Urinary bisphenol A and its interaction with CYP17A1 rs743572 are associated with breast cancer risk – Chemosphere

  6. 🧠 Animal-eRNAdb: a comprehensive animal enhancer RNA database – Nucleic Acids Research

  7. 🔬 Hepatocellular carcinoma risk variant modulates lncRNA HLA-DQB1-AS1 expression via a long-range enhancer–promoter interaction – Carcinogenesis

  8. 🧍‍♀️ Bisphenol A exposure, interaction with genetic variants and colorectal cancer via mediating oxidative stress biomarkers – Environmental Pollution

  9. 🧾 Discovery and Features of an Alkylating Signature in Colorectal Cancer – Cancer Discovery

  10. 🚨 Rising incidence of early-onset colorectal cancer — a call to action – Nature Reviews Clinical Oncology

📌 Conclusion:

Professor Rong Zhong is an outstanding and highly qualified candidate for the Best Researcher Award. Her prolific output, innovative approaches to cancer risk assessment, and leadership in national scientific research firmly position her among the top-tier researchers in her field. Her contributions have laid the groundwork for precision public health, with real potential to transform early cancer detection and prevention strategies in China and globally.